BR112023003696A2 - Compostos moduladores de gpr52 - Google Patents

Compostos moduladores de gpr52

Info

Publication number
BR112023003696A2
BR112023003696A2 BR112023003696A BR112023003696A BR112023003696A2 BR 112023003696 A2 BR112023003696 A2 BR 112023003696A2 BR 112023003696 A BR112023003696 A BR 112023003696A BR 112023003696 A BR112023003696 A BR 112023003696A BR 112023003696 A2 BR112023003696 A2 BR 112023003696A2
Authority
BR
Brazil
Prior art keywords
gpr52
modulating compounds
compounds
report
modulating
Prior art date
Application number
BR112023003696A
Other languages
English (en)
Portuguese (pt)
Inventor
Joanne Bucknell Sarah
Paul Watson Stephen
Alistair O'brien Michael
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of BR112023003696A2 publication Critical patent/BR112023003696A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Amplifiers (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112023003696A 2020-08-28 2021-08-31 Compostos moduladores de gpr52 BR112023003696A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2013558.8A GB202013558D0 (en) 2020-08-28 2020-08-28 GRP52 Modularor compounds
PCT/GB2021/052247 WO2022043714A1 (en) 2020-08-28 2021-08-31 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
BR112023003696A2 true BR112023003696A2 (pt) 2023-04-04

Family

ID=72749711

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003696A BR112023003696A2 (pt) 2020-08-28 2021-08-31 Compostos moduladores de gpr52

Country Status (12)

Country Link
US (1) US20230348416A1 (cg-RX-API-DMAC7.html)
EP (1) EP4204408A1 (cg-RX-API-DMAC7.html)
JP (1) JP7761635B6 (cg-RX-API-DMAC7.html)
KR (1) KR20230058132A (cg-RX-API-DMAC7.html)
CN (1) CN116507622B (cg-RX-API-DMAC7.html)
AU (1) AU2021330379A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003696A2 (cg-RX-API-DMAC7.html)
CA (1) CA3193487A1 (cg-RX-API-DMAC7.html)
GB (1) GB202013558D0 (cg-RX-API-DMAC7.html)
IL (1) IL301007B2 (cg-RX-API-DMAC7.html)
MX (1) MX2023002389A (cg-RX-API-DMAC7.html)
WO (1) WO2022043714A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
CN122555695A (zh) * 2023-11-29 2026-08-11 爱克堤欧生物科学股份有限公司 可用作kcnt1抑制剂的杂环化合物
CN121313618B (zh) * 2025-12-09 2026-07-21 杭州师范大学附属医院(杭州市第二人民医院) 丙酸在制备治疗肝豆状核变性肠肝轴紊乱的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373876B (es) * 2015-04-29 2020-03-26 Arena Pharm Inc 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.
WO2017077280A1 (en) * 2015-11-02 2017-05-11 Sonia Lain Tetrahydroindazoles and medical uses thereof
WO2021009003A1 (en) * 2019-07-16 2021-01-21 Universität Hamburg Computer-based identification of types in the empirical sciences by tangle theory
CN114650992A (zh) * 2019-11-08 2022-06-21 赫普泰雅治疗有限公司 Gpr52调节剂化合物

Also Published As

Publication number Publication date
CN116507622B (zh) 2026-02-24
IL301007B1 (en) 2026-04-01
IL301007A (en) 2023-05-01
WO2022043714A1 (en) 2022-03-03
US20230348416A1 (en) 2023-11-02
MX2023002389A (es) 2023-05-03
KR20230058132A (ko) 2023-05-02
EP4204408A1 (en) 2023-07-05
AU2021330379A1 (en) 2023-03-30
CN116507622A (zh) 2023-07-28
CA3193487A1 (en) 2022-03-03
IL301007B2 (en) 2026-08-01
JP2023539336A (ja) 2023-09-13
JP7761635B2 (ja) 2025-10-28
JP7761635B6 (ja) 2025-11-27
GB202013558D0 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
BR112022018287A2 (pt) Compostos moduladores de gpr52
BR112022008685A2 (pt) Compostos moduladores de gpr52
ZA202310378B (en) Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
MX2025015186A (es) Inhibidores de pi3k y uso de estos
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
WO2019191229A8 (en) Compounds for treating huntington's disease
BR0009044A (pt) Composto, composição farmacêutica, método para tratar uma doença em um animal, uso de um composto, e, processo para fabricar um composto
CO2021015264A2 (es) Inhibidores de dihidroorotato deshidrogenasa
ES2082875T3 (es) 3,5-di-terc-butil-4-hidroxifenilmetileno-derivados de tiazolidinonas, oxazolidinonas e imidazolidinonas 2-sustituidas utiles como agentes antiinflamatorios.
PT1543011E (pt) Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
BRPI0415350A (pt) pasta aquosa de polìmero superabsorvente e revestimento
BR112021016109A2 (pt) Derivados de protoporfirina ix e uso dos mesmos para melhorar a saúde das plantas
AR120785A1 (es) Innovación en composiciones ácidas modificadas
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
CL2024000742A1 (es) Compuestos moduladores de gpr52
DE602005025672D1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
WO2023129933A3 (en) 6,6-fused heterocyclic compounds as mettl3 inhibitors
MX2023002389A (es) Compuestos moduladores de gpr52.
BR112021018587A2 (pt) Compostos de heteroaril(heterociclil)metanol úteis no tratamento de hiperglicemia
ECSP23053033A (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
AR248153A1 (es) Una emulsion de aglomerante bituminoso de viscosidad controlada por adicion de esclerogucano.
ES479469A1 (es) Procedimiento para preparar 2-aminopirimidonas.
BR112021025103A2 (pt) Compostos antagonistas de cgrp
BR112021005759A2 (pt) composto, medicamento, métodos de modulação alostérica positiva e para a profilaxia ou o tratamento de constipação, e, uso do composto ou de um sal do mesmo

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NXERA PHARMA UK LIMITED (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]